Retrospective quantification of the genomic BCR‐ABL1 fusion sequence revealed persistence of the CML clone at a detectable level, illustrating the potential of supplementary DNA‐based MRD monitoring. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.